checkAd

     114  0 Kommentare Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Media

    A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient Derived Sample.

    MINNEAPOLIS, June 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, today announces that Predictive’s TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (PDx) through its distributor US Biological Corporation. The media used to grow the novel and unique ovarian cancer cell lines, licensed by TumorGenesis and its partner, GLG Pharma are able to retain 95%+ of the DNA and RNA as well as crucial proteomic signatures. The media was sold to a top rated medical university in the New England area for research in isolating and growing ovarian cancer cells from the fluid often found in the abdomen of women with advanced ovarian cancer, called the ‘ascites’ fluid. Ovarian cancer cell culturing from ascites fluids are notoriously difficult using standard media mixes often prone to failure and cell lines that are not representative of the patient’s ovarian cancer.

    A recent publication highlighted the waste in research using unvalidated media and reagents that showed an increase from $28 billion in 20151 to 2020 experiments are the foundation of preclinical research and development, however, irreproducibility rates in preclinical experiments exceed 50%, costing the industry nearly $48 billion annually2.

    “Capturing and culturing and then being able to study ovarian cancer cell types has always been limited by the ability to grow reproducible cultures that reflect what is in the patient”, said Richard Gabriel of TumorGenesis. “We now have isolated and grown 25 ovarian cancer cell types, 11 of that library, represents nearly 95% of all ovarian cancers, many of which have never been cultured prior to this time. This new media will allow researchers around the world to isolate and then culture ovarian cancer cell types and culture them reproducibly to find new targets for treatment, diagnostics or other studies on the close interrelationship of ovarian cancer tumor populations and how they are able to fool a patient’s immune system”, Mr. Gabriel highlighted.

    Seite 1 von 5




    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Media A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient Derived Sample. MINNEAPOLIS, June 18, 2020 (GLOBE …